Phase 3 N=806 The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome
Deep Venous Thrombosis
Primary: Incidence of Post-thrombotic Syndrome (PTS) — 44; 37 participants — p=.58
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=102 Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome
Acute Deep Vein Thrombosis
Primary: 2-year Change in Villalta Score — -1.5; -0.5 units on a scale — p=0.34
Phase 4 N=81 Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System
Deep Vein Thrombosis · Post-thrombotic Syndrome
Primary: Change From Baseline in Villalta Score at Day 30 Post-EkoSonic® Study Treatment Procedure — 15.5; -5.9 units on a scale
N/A N=27 Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
Venous Thrombosis · Neoplasms
Primary: PTS Assessment Completion — 17 Participants
N/A N=12 Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS)
Post Thrombotic Syndrome · Deep Vein Thrombosis · Venous Stasis Syndrome
Primary: Median Optimal Electrical Stimulation Intensity Level for Largest Benefit in Relief of Symptoms — 32 mirco coulombs (0 to 50)
Phase 3 N=692 Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56
Phase 3 N=1,217 COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
Covid19
Primary: Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial…
N/A N=189 Physical Therapy and Occupational Therapy After Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve Implantation
Primary: Post Procedure Hospital Length of Stay — 4.8; 3.5 days
N/A N=499 ClotTriever Outcomes (CLOUT) Registry
Deep Vein Thrombosis Leg · DVT · Chronic DVT of Lower Extremity
Primary: Primary Safety Endpoint: Proportion Participants With Major Adverse Events — 15 Participants
N/A N=1,175 Toronto Thromboprophylaxis Patient Safety Initiative
Venous Thromboembolism
Primary: Percentage of Patients Prescribed Appropriate VTE Prophylaxis — 64; 62; 67; 54 percentage of patients
Phase 4 N=28 Treatment of Upper Extremity Deep-Vein Thrombosis
Deep-Vein Thrombosis
Primary: Percentage of Participants That Died at 3 Months — 8; 0 percentage of participants
N/A N=10 Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study
Coronary Heart Disease
Primary: Brachial Flow Velocity — 21.0 cm/sec
N/A N=150 Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture
Rupture · Venous Thromboembolism · Venous Thrombosis
Primary: Venous Thromboembolic Events (VTE) — 26; 14 participants — p=0.042
N/A N=13,945 Treatment Patterns Among Patients With Venous Thromboembolism in the United States
Venous Thromboembolism
Primary: Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital — 11966; 1979 Participants
N/A N=407 Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism
Venous Thromboembolism · Venous Thrombosis
Primary: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs as Detected by Duplex Ultrasound — 1; 34 Participants — p=<0.001
N/A N=723 Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis (PREDICTORS)
Thromboembolic Disease Recurrent · Deep Vein Thrombosis · Pulmonary Embolism
Primary: Validation of the Wells DVT Clinical Decision Rule — 67; 186; 148; 4 Participants
Phase 3 N=410 Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery
Venous Thromboembolism
Primary: Number of Participants With Postoperative VTE Within 48 Hours After Surgery — 5; 3 participants — p=0.72
N/A N=116 JETi Lower Extremity Venous Thrombosis
Venous Thrombosis
Primary: The Primary Effective Endpoint: Percent of Treated Vessel(s) With ≥ 75% Venous Thrombus Reduction in Modified Marder Score (From Pre-JETi to Final) — 84.5 percentage of…
N/A N=8,256 Epidemiology of Thromboembolism Disease: A Cohort Study
Vascular Diseases · Embolism and Thrombosis · Phlebitis
Primary: Percentage of Participants Who Developed a New or Recurrence of Venous Thromboembolism (VTE) — 8.94 percentage of participants
Phase 3 N=2,856 Secondary Prevention of Venous Thrombo Embolism (VTE).
Thromboembolism
Primary: Composite of Recurrent VTE or VTE Death at 36 Months — 26; 18; 1404; 1408 Participants — p=0.0137
Phase 3 N=3,365 Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Pulmonary Embolism · Thromboembolism · Thrombosis
Primary: Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism — 13; 17; 50; 8 participants — p=0.0001
Phase 3 N=1,343 Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
Venous Thromboembolism
Primary: Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period — 3; 37 Participants — p=<0.0001
Phase 4 N=581 Chemoprophylaxis Plus Early Ambulation
Pulmonary Embolism · Thoracic Surgery
Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants
Phase 2 N=30 Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins
Acute Deep Venous Thrombosis of the Lower Extremity
Primary: Number of Participants With Restored Venous Function — 28 participants
N/A N=9 Intermittent Pneumatic Compression to Improve Revascularization Outcome
Peripheral Arterial Disease
Primary: Walking Endurance — -14; 35 Meters
N/A N=266,890 The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Venous Thromboses · Venous Thromboembolism · Deep Vein Thrombosis
Primary: Risk of Venous Thromboembolism (VTE) — 335; 845; 132; 3804 Participants
Phase 3 N=472 Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
Superficial Vein Thrombosis
Primary: Rate of Objectively Confirmed VTE Complications — 7; 4 Participants — p=0.0252
Phase 3 N=2,482 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Venous Thrombosis
Primary: Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With…
N/A N=204 Compression Therapy Following Endothermal Ablation
Varicose Veins
Primary: Patient's Post-procedure Pain Score Using a Visual Analogue Scale (VAS) — 18.7; 27.8 mm
N/A N=23 OsciPulse Device for the Prevention of VTE
Venous Thromboembolism · Deep Vein Thrombosis · Pulmonary Thromboembolisms
Primary: Part 1 - Subject's Response to Tolerability Questionnaire — 3; 0; 0; 0 Participants